univariate and multivariate analyses. Additionally, a TS gene polymorphism was analyzed with respect to the intratumoral protein levels. Results. Low TS expression in pretreatment biopsies correlated with impaired patient survival (p = 0.015). Analysis of a 28-bp repeat revealed a correlation between the *3/*3 genotype and high TS expression in pretherapeutic biopsies. In this study, a correlation of TS expression and grade of RCT-induced tumor regression was not found. Histopathological examination confirmed a complete tumor remission in 16 patients (9.6%). Analyses of the resection specimen indicated an unfavorable prognosis for patients with low intratumoral TS expression in case of detected lymph node metastases (p = 0.04). Conclusions. TS can serve as a prognostic biomarker indicating an unfavorable prognosis for patients with low TS expression.
During the past two decades, preoperative multimodal strategies and optimized surgical procedures, including total mesorectal excision (TME), have been increasingly used to treat UICC (Union International Contre le Cancer) stage II and III rectal cancer. [1] [2] [3] In particular, several studies have demonstrated that neoadjuvant 5-fluorouracil (5-FU)-based radiochemotherapy (RCT) significantly improves locoregional control, as well as sphincter preservation and the toxicity profile, compared with postoperative RCT. downsizing and UICC downstaging are important surrogate parameters, no reliable biomarkers for individual prognosis and response prediction to neoadjuvant RCT have yet been established. 6, [9] [10] [11] [12] With a 5-year distant relapse rate of 30-40%, the occurrence of systemic metastatic spread remains the predominant mode of failure and limits long-term prognosis. 7, 13 From the clinical point of view, the implementation of more risk-adapted therapy approaches is required. This notion applies to both the neoadjuvant part of multimodal treatment and the adjuvant situation because evidence on adjuvant chemotherapy (CT) is controversially discussed. 14, 15 Currently, ongoing clinical trials, such as the CAO/ARO/ AIO-04 trial [EudraCT-No: 2006-002385] 16 , are testing intensified neoadjuvant RCT for improving local complete response (pCR) and adjuvant CT to increase overall cancerspecific survival (CSS). Nevertheless, the approved antimetabolite and radiosensitizer 5-FU remains the backbone of systemic therapy. 17, 18 In 5-FU metabolism, thymidylate synthase (TS) is the central molecular target; TS is essential for de novo DNA synthesis. 19 A specific connection between TS expression and tumor cell viability was previously shown. 20 In several small-sized studies, the potential of TS as a valid biomarker has been investigated in multimodal treatment regimens; however, no final conclusion about its predictive and/or prognostic value has been gained. [21] [22] [23] Previous studies suggest that pretherapeutic TS expression may predict individual response to neoadjuvant 5-FUbased RCT in rectal cancer. [24] [25] [26] Additionally, the TS level in residual tumor specimens after RCT may be of prognostic value and allow stratification of patients with different risk profiles for recurrence. The purpose of this study was to evaluate the potential of TS as a predictive and prognostic biomarker in patients with rectal cancer, who were treated with standard preoperative 5-FU or 5-FU/ oxaliplatin protocols. TS protein levels were evaluated by immunohistochemical (IHC) staining of pretherapeutic biopsies and residual tumors after surgery. A tandem repeat polymorphism within the TS gene, which has been repeatedly discussed for the efficacy of 5-FU-based chemotherapy, was identified in the germline DNA extracted from the peripheral blood cells of these patients. 27 
PATIENTS AND METHODS

Eligibility and Clinical Assessments
Patients (mean age, 62.6 ± 9.5 years; 145 men and 63 women) with primary rectal cancer received 5-FU-based RCT within randomized clinical phase-II/-III-trials of the German Rectal Cancer Study Group (CAO/ARO/AIO-04, XelOX-trial, CAO/ARO/AIO-94). One hundred sixtyseven (80.3%) patients received neoadjuvantly 5-FU (n = 103) or 5-FU and oxaliplatin (n = 64) (Fig. 1) . Forty-one (19.7%) patients were conveyed to primary surgery, followed by adjuvant 5-FU RCT. All patients were treated at the Department of General and Visceral Surgery, University Medical Center Göttingen (Göttingen, Germany), between 1998 and 2009. Eligibility criteria included histologically confirmed adenocarcinoma, located no more than 16 cm above the anocutaneous verge, as measured by rigid rectoscopy, a complete medical history, physical examination, peripheral blood cell count, chest x-ray, abdominal ultrasound, and carcinoembryonic antigen (CEA) serum levels. 28 Furthermore, staging was completed by endorectal ultrasound (EUS) and contrastenhanced magnetic resonance imaging (MRI) of the pelvis to confirm locally advanced but resectable rectal cancer. Contrast-enhanced computed tomographic (CT) scans of the chest, abdomen, and pelvis were performed to identify patients with distant metastatic disease. At the time of staging, all patients had an Eastern Cooperative Oncology Group (ECOG) performance status of B2. 29 The study was approved by the medical ethics committee of the University of Göttingen.
Multimodal Treatment: Radiochemotherapy and Surgery
Preoperative radiotherapy with a total dose of 50.4 Gy was delivered in 28 fractions of 1.8 Gy in three-dimensional conformal irradiation by a three-field box technique with 20-MV photons. 30, 31 In 103 patients, 5-FU was scheduled as a 120-h infusion of 1,000 mg/m 2 per day during weeks 1 and 5. The same RCT regimen was applied postoperatively to the 41 patients receiving adjuvant RCT (Fig. 1) . In 64 patients who were randomized to an intensified protocol, neoadjuvant RCT was applied as a combination of 5-FU (250 mg/m 2 /d) days 1-14 and 22-35 and oxaliplatin (50 mg/m 2 /d) days 1, 8, 22, and 29. Six weeks after the completion of neoadjuvant RCT, curative surgery with TME was performed. 9 Four to six weeks after surgery, multimodal therapy was completed with four cycles of 5-FU (500 mg/m 2 /d) bolus infusion (days 1 to 5) or with eight cycles of 5-FU (2,400 mg/ m 2 ) continuous infusion with folinic acid (400 mg/m 2 ) and oxaliplatin (100 mg/m 2 ) bolus infusion ( Fig. 1) .
Histopathological Staging and Tumor Regression Grading
Complete pathological staging included ypTNM stage according to the current TNM classification; the evaluation of longitudinal and circumferential resection margins with an aimed tumor distance of B1 mm and intramural or extramural vascular and perineural invasion and the quality assessment of TME based on MERCURY criteria. [32] [33] [34] [35] Nodal staging included the histological evaluation of all detected lymph nodes and the determination of lymph node ratio in all cases.
Histopathological Staging and Classification of Tumor Response
RCT-induced tumor regression was denoted based on a semiquantitative five-point tumor regression grading (TRG) system. 6, 36 pCR was defined as the absence of any viable tumor cells in the primary tumor and all detected lymph nodes. 37 The standardized clinical setting and specimen preparation warrants a marginal bias, according to the REMARK guidelines for biomarker studies. 38 
Follow-up
During treatment, all patients were monitored on a weekly basis. Long-term follow-up included rectoscopy, abdominal ultrasound, computed tomography of the abdomen and pelvis, as well as chest x-ray at regular intervals according to the study protocols. Disease-free survival (DFS) was defined as the interval between surgical resection and any evidence of local or systemic cancer recurrence. Histologic confirmation of cancer recurrence was encouraged. Alternate acceptable criteria included specific imaging findings with concurrent elevation of CEA serum levels. CSS was defined as the interval between surgical resection and cancer-related death. Follow-up examinations were performed at 3-month intervals within the first 2 years and at 6-month intervals after 2 years. 8 
Tissue Samples and Immunohistochemical Evaluation of TS Expression
Tumor specimens were collected at the time of the first biopsy procedure and at the time of surgery (Fig. 1) . The TS protein level was assessed on paraffin-embedded, matched tissue samples from pretreatment tumor biopsies and surgical specimens from the same patients. A standardized immunohistochemical staining technique was performed using a Ventana BenchMark XT immunostainer (Ventana, Tucson, AZ) with a mouse anti-human monoclonal antibody to TS (anti-human TS [Rabbit] Code: 100-401-199 Rockland, PA) at a dilution of 1:100. Heat epitope retrieval using the immunostainer was performed for 60 min at 100°C. The anti-TS antibody was incubated at 37°C for 28 min. The enzymatic reactivity was visualized with alkaline phosphatase (Red Detection Kit, Roche Ventana, Mannheim, Germany).
The immunohistochemical slides were independently evaluated and interpreted by two different observers in a blinded manner, without the knowledge of the clinical and follow-up data. TS immunoreactivity was scored for staining intensity ( Fig. 2 ) and proportion of positive cells when at least 50 tumor cells were accessible. The slides were screened at a low power for pattern and distribution of staining; a higher magnification (940) was used to determine the staining intensity. To record antibody expression, the scoring method by Remmele and Stegner 39 was adopted and slightly modified to incorporate heterogeneous staining intensities and to obtain a more accurate score. Staining was semiquantitatively evaluated as follows: staining intensity was scored as none (0), weak (1), moderate (2), and strong (3). The tumor cell percentage of each of these four intensity classes was documented (as q 0 , q 1 , q 2 , and q 3 , respectively). The tumor percentage (s) was defined as the total percentage of positive tumor cells (q 1 ? q 2 ? q 3 ). The tumor cell percentage was categorized into five groups: 0 = 0%; 1 = (0-25%); 2 = (25-50%); 3 = (50-75%); 4 = (75-100%), as the tumor percentage score. The weighted mean of the staining scores weighted by the observed percentages (1(q 1 /s) ? 2(q 2 /s) ? 3(q 3 /s))/3 was calculated and defined as the tumor staining intensity score. For further statistical analysis, the tumor staining intensity score (range 0-3) and the tumor percentage score (range 0-4) were multiplied to obtain the final TS score (range 0-12). In Kaplan-Meier analyses, low TS expression was defined as a TS score \7 and high expression as TS scores C7, according to the observed median. Likewise, the cutoff score applied for analyses of pretherapeutic biopsies was set to 4, in accordance with the median.
Genotyping of TS 28-bp Tandem Repeats
In the TS gene, the number of the TS 28-bp repeat polymorphism (abbreviated as 28R, rs34743033 according to the dbSNP database: http://www.ncbi.nlm.nih.gov/snp) was genotyped in lymphocytes by fragment length analysis. At first, the genomic fragment containing this repeat was amplified by conventional PCR using Taq polymerase with Q-solution (Qiagen, Hilden, Germany) with FAM labeling of one primer at the 5 0 end. PCR conditions were 35 cycles, each consisting of a 50-s denaturation at 95°C, a 30-s annealing at 68.5°C, and a 60-s elongation at 72°C. Primer sequences (each in 5' to 3' direction) were GTGGCTCCTGCGTTTCCCC and FAM-TCCGAGCCG GCCACAGGCAT, yielding the fragments of 212 bp (in case of two 28R repeats, denoted as 28R*2), 240 bp (three 28R repeats, 28R*3), and, as found only once, 268 bp (four 28R repeats, 28R*4). 40 The fragments with the FAMlabeled primer were analyzed on a sequencing machine (3100 Genetic Analyzer, Applied Biosystems, Foster City, CA). Genescan 400HD (Applied Biosystems) was used as the size standard to allocate fragment length. Determined genotypes were in Hardy-Weinberg equilibrium, as assessed by v 2 test (p = 0.8).
Statistical Analysis
Correlation analysis of the TS score with clinical outcome variables was assessed using the Spearman correlation coefficient and was tested for statistical significance. The impact of the TS score on DFS and CSS was statistically tested using Cox proportional-hazards regression models. For graphical display, the TS score was categorized as low or high and was expressed as a Kaplan-Meier plot. The comparative analysis of patients' clinicopathological characteristics between different groups was performed using a v 2 test. To confirm the prognostic value of further clinicopathologic parameters, these factors were tested in a multivariate model. Additionally, the impact on the following variables that were available at the time of staging (gender, age, uN, uT, planned neoadjuvant treatment, and TS score in a Cox model from the staining of the biopsy) were assessed both in univariate analyses and a multivariate model. The TS scores of all patients with lymph node metastases after resection also were analyzed, including the following variables: (y)pT, applied neoadjuvant treatment and pretherapeutically measured TS score from tumor biopsy in a multivariate model. The global significance level was set to a = 5%. All statistical analyses were performed using the R statistical computing environment version 2.11.0. 41 
RESULTS
Patient Characteristics and Recurrence
With respect to the primary tumor localization of rectal adenocarcinoma at staging (Table 1) , 82 (39.4%) tumors (Table 1) .
Pretherapeutic TS expression in Correlation with Tumor Regression Grading
The current study did not reveal a correlation between pretreatment TS expression and RCT-induced histopathological tumor regression (TRG). TRG had no prognostic impact on DFS in this study, unless a complete tumor remission was achieved (p = 0.46; r = -0.16). Nevertheless, the long-term survival of patients with pCR after neoadjuvant RCT and extensive histopathological workup was excellent because no patient with pCR (n = 16; 9.5%) exhibited cancer recurrence during the follow-up time.
PRETHERAPEUTIC TS EXPRESSION AND PROGNOSIS
TS expression in pretherapeutic biopsies showed a significant correlation with cancer-related death, demonstrating a benefit for patients with high TS expression (p = 0.0406; Fig. 3 ). The multivariate analyses (Table 2) of pretreatment TS score and other parameters available at the time of initial staging (age, uN, uT, and neoadjuvant treatment) revealed a significant correlation of low TS expression with a decrease in CSS (p = 0.01) and confirmed baseline TS expression levels as an independent prognostic marker.
Prognostic Value of Intratumoral TS Expression in Resected Specimens
In patients with histologically confirmed lymph node metastases, intratumoral TS expression of the resected tumor specimens showed prognostic relevance. There was a significant decrease of DFS (p = 0.015) in patients with lymph node metastases (n = 74) and low TS expression (Fig. 4) .
Included in a multivariate cox regression model (Table 2) , TS expression in nodal-positive patients was significantly associated with a decreased DFS (p = 0.03).
Findings in Patients with ypN0 Status
In nodal-negative patients, TS expression had no influence on DFS (p = 0.168). Furthermore, no significant differences in local and distant recurrences were observed within the three groups of patients.
TS Genotype does Correlate with Intratumoral TS Protein Expression
Genotypes of all patients with available blood samples (n = 152) for the TS 28-bp tandem repeat polymorphism revealed the following distribution: 39 patients (25.7%) with *3/*3; 74 patients (48.7%) with *3/*2; 38 patients (25%) with *2/*2; and 1 patient with the *2/*4 allele. The correlation of the TS genotype *3/*3 with TS protein expression revealed a trend of higher expression levels in biopsy specimens (p = 0.059) and tumor specimens (p = 0.229), but the difference was not statistically significant.
This result is consistent with the findings from previous analyses that revealed a coherency of several 28-bp repeats with higher intracellular TS expression. 42 The statistical analysis of the TS genotype with local response, other clinicopathological findings (TRG, T-level downsizing, UICC downstaging, ypN and ypT status), DFS, and overall survival did not reveal any association in the analyzed patient cohort that could currently be used for a specific risk assessment.
DISCUSSION
Our analysis is the largest study so far to characterize TS expression from pretherapeutic biopsies and the corresponding surgical specimens from patients with rectal cancer treated in multimodal concepts. 22 Although previous analyses of smaller patient cohorts reported high TS expression as a negative prognostic biomarker, recent data, in accordance with our present findings, have shown a benefit for patients with high intratumoral TS expression. 23, 25, [43] [44] [45] [46] Within previous studies, Jakob et al. 43 evaluated TS expression levels in 40 patients and found a correlation between low TS expression and TRG. In patients with RCTinduced pCR (TRG-4), we observed an excellent clinical course without any cancer recurrence during the follow-up period. Moreover, tumor regression grades between 1 and 3 did not predict long-term survival. In further analyses, based on a very small patient cohort, Jakob et al. postulated that high TS levels indicated unfavorable prognosis in patients with cancer recurrence (n = 9) without RCT-induced UICC downstaging. This hypothesis was supported by several other studies as reviewed by Kuremsky et al. 22 ; however, they primarily investigated the correlation with local response parameters, out of the context of DFS and overall survival. Other reasons for opposite conclusions of previous studies might be rooted in a lack of differentiation between colon and rectal cancer, limited analyses with results derived from small subgroups, and finally different methodological approaches.
We evaluated TS protein level by IHC, because it can be easily implemented into clinical routine. Another approach to investigate the impact of TS was the pharmacogenetic analysis of gene polymorphisms. 47 A comparative analysis of quantitative TS protein expression detected by IHC and genotype also confirmed the coherence of the TS polymorphism with intratumoral expression activity. Aside from the analyses of single nucleotide polymorphisms, a 28-bp repeat within the TS gene seems to be of interest. 42, 48, 49 A correlation between the number of 28-bp repeats and gene and protein expression efficacy has been repeatedly found and confirmed by our investigations. 50, 51 Low TS expression from pretherapeutic biopsies showed prognostic value with respect to impaired CSS. Based on these findings, one could conjecture a benefit from the intensification of neoadjuvant RCT protocols, especially for patients who do not sufficiently respond to preoperative RCT with 5-FU monotherapy. Indeed, a better outcome for patients with low TS expression was observed under the intensified treatment with 5-FU and oxaliplatin, although these data originated from a subgroup analysis. A prospective validation of this observation in a large patient cohort would be crucial for implementing the pretherapeutic TS expression level assessment into clinical practice. Within a prospectively randomized clinical trial, stratification of patients for the neoadjuvant RCT regimen as well as for the adjuvant treatment according to TS expression and further markers for the patients' individual risk would be the next step toward individualized therapy.
CONCLUSIONS
This study demonstrates the prognostic value of TS in locally advanced rectal cancer treated with multimodal 5-FU-based RCT. The analyses show an unfavorable prognosis in patients with low intratumoral TS expression. Standardized IHC staining could easily integrate TS analysis into routine staging procedures and could be used for stratification of adjuvant therapy. Particularly, patients with persistent positive lymph node status and low TS expression in the resected specimen are at a higher risk for cancer recurrence. These patients might benefit from an intensified treatment regime and potential higher rates of therapyassociated toxicity might be justified. Prospective validation in future clinical trials is crucial for legitimating the treatment stratification based on the TS expression level.
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